174 related articles for article (PubMed ID: 17706166)
21. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
[TBL] [Abstract][Full Text] [Related]
22. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma.
Brandt L; Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
24. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
25. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.
Deconinck E; Miadi-Fargier H; Pen CL; Brice P
Pharmacoeconomics; 2010; 28(1):35-46. PubMed ID: 20014875
[TBL] [Abstract][Full Text] [Related]
27. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
28. Prolonged molecular and clinical remission after treatment of a patient with follicular lymphoma with rituximab.
Buckstein RJ; Rimrie K; Pennell N; Spaner D; Hewitt K; Berinstein NL
Leuk Lymphoma; 2001 Apr; 41(3-4):451-5. PubMed ID: 11378562
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
30. Increasing treatment options in indolent non-Hodgkin's lymphoma.
Solal-Céligny P
Semin Oncol; 2002 Apr; 29(2 Suppl 6):2-6. PubMed ID: 12040527
[TBL] [Abstract][Full Text] [Related]
31. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
32. Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
Cohen Y; Libster D; Da'as N; Amir G; Polliack A
Hematol J; 2003; 4(2):151-3. PubMed ID: 12750735
[TBL] [Abstract][Full Text] [Related]
33. Principles of maintenance therapy.
Berinstein NL
Leuk Res; 2006 Mar; 30 Suppl 1():S3-10. PubMed ID: 16750676
[TBL] [Abstract][Full Text] [Related]
34. Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma.
Yared J; Kimball A; Baer MR; Bahrain H; Auerbach M
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):253-7. PubMed ID: 23352637
[TBL] [Abstract][Full Text] [Related]
35. Rituximab maintenance therapy of relapsed or refractory follicular lymphoma, with longer follow-up: no proven impact on survival.
Prescrire Int; 2012 Mar; 21(125):63. PubMed ID: 22428183
[TBL] [Abstract][Full Text] [Related]
36. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
[TBL] [Abstract][Full Text] [Related]
38. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
Ternant D; Cartron G; Hénin E; Tod M; Girard P; Paintaud G
Br J Clin Pharmacol; 2012 Apr; 73(4):597-605. PubMed ID: 21999172
[TBL] [Abstract][Full Text] [Related]
39. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
[TBL] [Abstract][Full Text] [Related]
40. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
